{"ticker": {"uuid": "fc2816e8-a88e-4e86-8f56-2c6539138e00", "symbol": "DNTH", "name": "Dianthus Therapeutics Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Form 4 Dianthus Therapeutics Inc For: 13 July By Investing.com", "summary": "This article from Investing.com reports that Dianthus Therapeutics Inc. submitted a Form 4 on July 13. The company's stock symbol is DNTH, and it experienced a slight increase of 0.96% at the time of publication. The brief report serves as an announcement for the financial filing", "url": "https://ng.investing.com/news/stock-market-news/form-4-dianthus-therapeutics-inc-for-13-july-93CH-2597649", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T22:14:00", "published_display": "13 Jul 2026 22:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus therapeutics CFO Ryan Savitz sells $3.16 million in shares", "summary": "Dianthus Therapeutics CFO Ryan Savitz sold 31,249 shares of common stock for approximately $3.16 million on July 9, 2026, through a Rule 10b5-1 trading plan. This sale occurred after he exercised stock options to acquire the same number of shares, which were vested monthly over f", "url": "https://www.investing.com/news/insider-trading-news/dianthus-therapeutics-cfo-ryan-savitz-sells-316-million-in-shares-93CH-4789441", "source_name": "Investing.com", "published_at": "2026-07-13T21:41:03", "published_display": "13 Jul 2026 21:41", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Dianthus Therapeutics, Inc. /DE/ Insider Trading Activity", "summary": "Dianthus Therapeutics' EVP, CFO & CBO, Ryan Savitz, exercised stock options for 31,249 shares and subsequently sold them in open-market transactions for approximately $3.16 million, as detailed in a recent Form 4 filing. These sales were conducted under a Rule 10b5-1 trading plan", "url": "https://www.stocktitan.net/sec-filings/DNTH/form-4-dianthus-therapeutics-inc-de-insider-trading-activity-8c7fd1efe021.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:41:03", "published_display": "13 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Dianthus Therapeutics (DNTH) Starts Phase 3 EMERGE Trial, Is The Upside Already Priced In?", "summary": "Dianthus Therapeutics (DNTH) has initiated its Phase 3 EMERGE trial for claseprubart in generalized Myasthenia Gravis, and the stock has experienced significant appreciation recently. Despite a high valuation compared to the broader biotech industry, it appears undervalued agains", "url": "https://www.sahmcapital.com/news/content/dianthus-therapeutics-dnth-starts-phase-3-emerge-trial-is-the-upside-already-priced-in-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-11T02:40:38", "published_display": "11 Jul 2026 02:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing", "summary": "This article details a Form 144 SEC filing by Dianthus Therapeutics, Inc. (DNTH) concerning a proposed sale of 31,249 common shares with an aggregate market value of $3,064,589.43. The shares were acquired on July 9, 2026, through the exercise of stock options and are intended to", "url": "https://www.stocktitan.net/sec-filings/DNTH/144-dianthus-therapeutics-inc-de-sec-filing-220316c7136d.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:03:53", "published_display": "09 Jul 2026 20:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Dianthus Therapeutics, Inc. \u2013 MUN:87E", "summary": "The article provides a simple statement about the \"Price to earnings forward\" for Dianthus Therapeutics, Inc. (MUN:87E) on the Munich Stock Exchange. It indicates no trading activity and shows a placeholder for a period, value, and change, suggesting that specific financial data ", "url": "https://www.tradingview.com/symbols/MUN-87E/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T11:10:38", "published_display": "08 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Dianthus Therapeutics, Inc. \u2013 NASDAQ:DNTH", "summary": "This article provides an analysis of the enterprise value to revenue forward for Dianthus Therapeutics, Inc. (NASDAQ: DNTH). It appears to be a financial snapshot from TradingView, highlighting key financial metrics for the company. The content focuses on the valuation of the com", "url": "https://www.tradingview.com/symbols/NASDAQ-DNTH/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T04:11:21", "published_display": "06 Jul 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DNTH - Dianthus Therapeutics Inc Revenue Breakdown", "summary": "This article provides a comprehensive financial overview of Dianthus Therapeutics Inc (DNTH), detailing its revenue breakdown, key financial metrics, stock performance, and insider/institutional ownership. It includes various ratios like P/S, P/B, and profitability margins, along", "url": "https://finviz.com/stock?t=DNTH&ta=1&p=d&ty=rv&b=2", "source_name": "Finviz", "published_at": "2026-07-05T13:44:31", "published_display": "05 Jul 2026 13:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)", "summary": "Dianthus Therapeutics, Inc. announced that it granted equity awards to five newly-hired, non-executive employees on July 1, 2026. These inducement grants, approved by the independent Compensation Committee, consist of non-qualified stock options to purchase an aggregate of 58,000", "url": "https://finance.yahoo.com/healthcare/articles/dianthus-therapeutics-announces-inducement-grants-200100668.html", "source_name": "Market source", "published_at": "2026-07-03T12:10:57", "published_display": "03 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus gives 5 new hires stock options worth 58,000 shares", "summary": "Dianthus Therapeutics granted 58,000 non-qualified stock options to five new non-executive employees on July 1, 2026, as an inducement under Nasdaq Listing Rule 5635(c)(4). These options have a 10-year term, an exercise price of $90.21 per share, and a four-year vesting schedule.", "url": "https://www.stocktitan.net/news/DNTH/dianthus-therapeutics-announces-inducement-grants-under-nasdaq-2dq42355f5jn.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:40:34", "published_display": "02 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics (DNTH) Starts Phase 3 Trial, Is The Stock Still A Bargain?", "summary": "Dianthus Therapeutics (DNTH) is gaining attention after initiating its EMERGE global Phase 3 trial for claseprubart in generalized Myasthenia Gravis, following positive Phase 2 data and Orphan Drug Designation. Despite recent volatility and removal from Russell indices, the stock", "url": "https://www.sahmcapital.com/news/content/dianthus-therapeutics-dnth-starts-phase-3-trial-is-the-stock-still-a-bargain-2026-07-02", "source_name": "Sahm", "published_at": "2026-07-02T13:44:31", "published_display": "02 Jul 2026 13:44", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Dianthus Therapeutics, Inc. \u2013 NASDAQ:DNTH", "summary": "This article provides a financial metric, \"Price to book forward,\" for Dianthus Therapeutics, Inc. (NASDAQ: DNTH). It is presented on the TradingView platform, which offers various financial tools and data for investors. The content is primarily a listing of navigation and footer", "url": "https://www.tradingview.com/symbols/NASDAQ-DNTH/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T22:39:20", "published_display": "01 Jul 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Dianthus Therapeutics (DNTH) Is Up 11.4% After Launching Its Phase 3 EMERGE gMG Trial", "summary": "Dianthus Therapeutics saw its stock rise by 11.4% after initiating the global Phase 3 EMERGE trial for its investigational antibody claseprubart in generalized Myasthenia Gravis (gMG). This follows promising Phase 2 data and FDA Orphan Drug Designation. The trial aims to offer an", "url": "https://www.sahmcapital.com/news/content/why-dianthus-therapeutics-dnth-is-up-114-after-launching-its-phase-3-emerge-gmg-trial-2026-07-01", "source_name": "Sahm", "published_at": "2026-06-30T12:40:27", "published_display": "30 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics stock hits 52-week high at 96.85 USD", "summary": "Dianthus Therapeutics (DNTH) stock has hit a new 52-week high of $96.85, achieving a market capitalization of $5.21 billion and demonstrating significant growth with a 1-year total return of over 440%. Despite an InvestingPro analysis suggesting it may be overvalued, the company'", "url": "https://www.investing.com/news/company-news/dianthus-therapeutics-stock-hits-52week-high-at-9685-usd-93CH-4765607", "source_name": "Investing.com", "published_at": "2026-06-29T14:40:21", "published_display": "29 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics stock hits 52-week high at 96.85 USD By Investing.com", "summary": "Dianthus Therapeutics stock has reached a 52-week high of $96.85, pushing its market capitalization to $5.21 billion, despite an InvestingPro analysis suggesting it might be overvalued. The company has seen significant growth with a 440.84% 1-year return and 131% year-to-date gai", "url": "https://ca.investing.com/news/stock-market-news/dianthus-therapeutics-stock-hits-52week-high-at-9685-usd-93CH-4711951", "source_name": "Investing.com Canada", "published_at": "2026-06-29T13:39:43", "published_display": "29 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 84, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics Begins Phase 3 Trial of Treatment for Rare Autoimmune Disorder", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/dianthus-therapeutics-begins-phase-3-120515696.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:05:15+00:00", "published_display": "29 Jun 2026 12:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis", "summary": "Dianthus Therapeutics has initiated the Phase 3 EMERGE trial for claseprubart, a treatment for generalized Myasthenia Gravis (gMG). This global, randomized, placebo-controlled study will evaluate subcutaneous doses of claseprubart in approximately 195 participants, with top-line ", "url": "https://www.manilatimes.net/2026/06/29/tmt-newswire/globenewswire/dianthus-therapeutics-announces-initiation-of-phase-3-emerge-trial-of-claseprubart-in-generalized-myasthenia-gravis/2374736", "source_name": "The Manila Times", "published_at": "2026-06-29T10:39:43", "published_display": "29 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus launches Phase 3 study of claseprubart in rare muscle disease", "summary": "Dianthus Therapeutics has initiated the global Phase 3 EMERGE trial for claseprubart in patients with generalized myasthenia gravis (gMG) who are AChR+. This placebo-controlled study will involve approximately 195 participants to evaluate subcutaneous dosing regimens (Q2W and Q4W", "url": "https://www.stocktitan.net/news/DNTH/dianthus-therapeutics-announces-initiation-of-phase-3-emerge-trial-3bfqpf2ebwxk.html", "source_name": "Stock Titan", "published_at": "2026-06-29T10:39:43", "published_display": "29 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics, Inc.(NasdaqCM: DNTH) dropped from Russell 3000E Index", "summary": "Dianthus Therapeutics, Inc. (NasdaqCM:DNTH) has been removed from the Russell 3000E Index. The company, a clinical-stage biotechnology firm, focuses on developing therapies for severe autoimmune diseases with lead candidates like claseprubart and DNTH212. Recent news includes pre", "url": "https://www.marketscreener.com/news/dianthus-therapeutics-inc-nasdaqcm-dnth-dropped-from-russell-3000e-index-ce7f5fdede89f622", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T09:48:47", "published_display": "29 Jun 2026 09:48", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell Microcap Growth Benchmark Index", "summary": "Dianthus Therapeutics, Inc. (NasdaqCM:DNTH) has been removed from the Russell Microcap Growth Benchmark Index. The company is a clinical-stage biotechnology firm developing therapies for severe autoimmune diseases, with its lead candidate, claseprubart, undergoing multiple clinic", "url": "https://www.marketscreener.com/news/dianthus-therapeutics-inc-nasdaqcm-dnth-dropped-from-russell-microcap-growth-benchmark-index-ce7f5fded08df721", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T08:40:00", "published_display": "29 Jun 2026 08:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Dianthus Therapeutics, Inc. \u2013 NASDAQ:DNTH", "summary": "This article provides financial information for Dianthus Therapeutics, Inc. (NASDAQ: DNTH), specifically its price-to-sales forward metric. The content was sourced from TradingView and includes data from ICE Data Services and FactSet.", "url": "https://www.tradingview.com/symbols/NASDAQ-DNTH/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T22:39:43", "published_display": "28 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Dianthus Therapeutics, Inc. \u2013 NASDAQ:DNTH", "summary": "This article provides the \"Price to earnings forward\" value for Dianthus Therapeutics, Inc. (NASDAQ: DNTH). It appears to be an unpopulated data point from a financial platform like TradingView, indicating that the specific financial metric is not available for the company at the", "url": "https://www.tradingview.com/symbols/NASDAQ-DNTH/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T16:09:43", "published_display": "28 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DNTH - Dianthus Therapeutics Inc Options", "summary": "This article provides a comprehensive financial snapshot of Dianthus Therapeutics Inc (DNTH), a biotechnology company. It details key financial metrics including market capitalization, revenue, earnings, insider and institutional ownership, profitability ratios, and stock perform", "url": "https://finviz.com/stock?t=DNTH&ta=1&p=d&ty=oc&b=2&ov=chain_strike&s=75", "source_name": "Finviz", "published_at": "2026-06-28T12:10:57", "published_display": "28 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Dianthus Therapeutics, Inc. \u2013 DUS:87E", "summary": "This article provides the \"Price to book forward\" for Dianthus Therapeutics, Inc. (DUS:87E) on the Dusseldorf Stock Exchange. It indicates that the market is currently closed with no trades recorded. The content seems to be a financial data point from a trading platform.", "url": "https://www.tradingview.com/symbols/DUS-87E/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:42:03", "published_display": "28 Jun 2026 06:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DNTH Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast for Dianthus Therapeutics, Inc. (DNTH) stock, including a 1-year price target of 127.85 USD based on 13 analysts. It details recent stock performance, analyst estimates for future prices ranging from 98.00 USD to 200.00 USD, and financial metrics s", "url": "https://www.tradingview.com/symbols/NASDAQ-DNTH/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T09:42:04", "published_display": "27 Jun 2026 09:42", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics, Inc. Actuals & Estimates (FWB:87E)", "summary": "This article provides an overview of Dianthus Therapeutics, Inc. (FWB:87E) financial actuals and estimates, stock performance, and analyst forecasts. It covers the current stock price, historical highs and lows, market capitalization, earnings reports, and volatility. The company", "url": "https://www.tradingview.com/symbols/FWB-87E/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:41:51", "published_display": "26 Jun 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A3ERZ4 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Dianthus Therapeutics, Inc. (A3ERZ4) stock, including analyst price targets, historical performance, and key financial metrics. It details the company's valuation, earnings, revenue, and market capitalization, offering insights into its stock ", "url": "https://www.tradingview.com/symbols/LSX-A3ERZ4/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T13:39:53", "published_display": "25 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus (DNTH) SVP uses 10b5-1 plan to sell 30,000 shares", "summary": "Dianthus Therapeutics' SVP and General Counsel, Adam M. Veness, reported an exercise-and-sale transaction involving 30,000 shares of company stock. He exercised stock options at $17.88 per share and subsequently sold the same number of shares in open-market transactions under a R", "url": "https://www.stocktitan.net/sec-filings/DNTH/form-4-dianthus-therapeutics-inc-de-insider-trading-activity-bf0f74c97bb0.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:40:19", "published_display": "18 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus CIDP Data Lift Prospects While Funding And Dilution Risks Linger", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/dianthus-cidp-data-lift-prospects-110917568.html", "source_name": "Simply Wall St.", "published_at": "2026-06-15T11:09:17+00:00", "published_display": "15 Jun 2026 11:09", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Dianthus Therapeutics stock plunging today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPMlYxTVR2dHhDSVhxd0xjQV84NUFob1NDWXpHYlZPX1hlZ2xRYW50eW01QkJTYXNYekdVTUxZX2phZ3EyQUEyWE5sWl9pcjlYUDFUTmE3Nkp1STJmRE5xMHBWWnZZalZBeVBRS0hDQTdPTEVfRll3RmhJTnJScE9WanJVZUhFcHRyT0dRWlVsZ3ByS0psempReVdQd0dXRFdrT0JnQkYxUktzVkhCaDVFdw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus drops as Sanofi halts trial for peer drug (DNTH)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPUmJuYTNodk13NTgxdGFJNHZvdExsVUZ2cl9pVHJvbjA1eF85cDVxOF85SEdhYWxiLXQ3NmdGdWRRMEY1S0RiNkw1NWZrTFhmV2E1NWVsUTVZUTNsdTBxYWRwSVB5RTU2MThMTUpqVUpJdy02QzNfa1MxN1UtVFVudUhIOEtRamdG?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQREtnY2xmZ0NTV3V5TmRPRG9CN1dLZ0hPbHNYb3RsdWtoSGdCX3U2QkhMUk1aM2tKcWtUbjJ5VjFJRXpCREZhLWlodldUekd1M0xNVjFZSVF2a2xuYVZNWTZXYlZCb0RZODJMUlVEQzM2Y2lva2NoVEdoTlA0NF9XUml1bWZqWkFVWHNkdG1pYkRLUzluZlI0eUlWRzVXYkU5bzNDRE05RnFJODFuakluQkhrNms?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNRUVBTUtfWWZpUU14T3RxRURWWEZERlJBb0hSNEdOQlBZQXhQU0tBbnl1R1ZWYnk5M3NJNmZmcFVmNDI3TWJGV2h3VW85dTQ0VXRoeENQLW9VWEhtTVRrc282YnN1ZDFZLWMxWmpDWDBnZExRa0d6NC1uNS04S1FBMXdWSUxZXzdudGt3OGtaalVCY05rMl9ZajFNS0JqbVh6eXhiUDJB?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DNTH (NASDAQ) director files Form 144 to sell 26,530 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNMi0wMkZaR1dCLVpodUo1QWZFLVpDRW9MeWFrSXMyWUNfQWNxa0RINUttZS1sc3ZrOGVyc1NIcERKb1lMc2hfcW5aY0J0a0liMkNSTzEzc0JacU1GLVVYUkxtTUtySlQtN21NNHYxTDlxUGxuMWlqQzhsT1lrSHI1OXZjclByQzFuZmlMM0doNlFCcWkyNTVWRGMyejBKUjJ0ZXJyS2lCQUk?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Dianthus to meet investors at Jefferies and Goldman events", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOYWJDNnVNejZCbkpIUklOaTRIWkk4ckhDMU5rVFNrVWRoRFd5S3gyZTNsSDhKWFEyZzEyaGxFVXRybk1FalBmX1JqZU5JZkdMYi1neG1IRkw5NDd0NENtd2lfUUlIM21uanJfXy16c19WSV9LNk9yOGk1QzdHeXU0RmtjWUZLTXBsMkFNOVBaVTJqZldJZEFfTUVnc2RIcmdLQVhlOElzOWR3SEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOR1BicF9Ma2kzSmpXeV95c1dxNG9vUkdVSmRFdklyYU80MDFhWE9lV2VqQU1TM0lSYS1abkxWSE9hUm82bXZKb1JUTEdrVk9weGNWNldjRU95OWx5QkVlZ1NVOW81M1dlU1NBR3NDa2xSUU9YeUJBaHRvTnVwOWc2cTdwMTJDUjNkS0RFZGxUZ0VGSk5MWnVmUlp2LU1sOUJoVk9ZMHdTUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Dianthus got 20 responders before 40 patients in CIDP trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOejJVVWZfS254RF9oZUdiS0Zwb1hNaF9Ha0pNR0hLSHJYYkxSN1FacmYtOXRBQjZFMEpkS2NRQ3RodThrc2hxTjA0NXZuVHJtS0NSUzdwbk1WaXNtUlZ5ZlE4WmJHczh0cWZvUVpZSEU5V3ZzNElQSHFMeEtmcVhPNld1LXZTQW5uQ1FFTDNXWmFPWkpTWklUVWlkU280ZWdHSXhrWklOcXJNTWh1S0VqRUx3ZHJXVkFFN185SQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQTHJ2eHdfZ2N3cXd3NVB3c01iV1plZGRMZ3dTSER4RmtFYU1FazdiOHkwbE4xR2dsR3FpVlRnR012dXVvVkx1X3UzS2tNR0RranZvU1lOdkd1ZmdfajFmYXV2X1BWZG0wWjlobDZNMXB0eV93QUdtVDBkaTBWSmxVd3VEWUtfMGxtWTNUTmtyT2ttM0lacTRXUmg5WUdYaTdBSmtWc0JPMDlwb2s?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPblBaR0hLZ3lSSTdjZThTSWFuV3VkTkVRZ3ZJeWp2SXEyQWhnNmlrUmFiNlhNZWttaVZmc01tSDBWbmZnTlhXVVpsTmNfNWtTV25VR1lQekx6bzczeEZSQ0hwN3dsZ1BUNnRaTDl5MG01eFM3M2JPcVRmUWxBUzlVZDNrWHRoSThJdEJEQzlDRmVTQUlMSnJBenZIVVRka2NFcUFySl96bw?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotech Dianthus raises $719M to push autoimmune disease drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNeDZseEVCOG1Bajg2UVJyVTlDYmtTRGk0NUtndXh3anE1Z2w3VEtsVXZGRzBrWmFEVWthY0VWSVpGS3NVeEdHbnp4VE91VktMcVZ6dmQ4YXpNNW9HZkhFcm90a0s0VTczNEZ5RlFPQW5rMUxIT2tDTHhIUnplQzlqeWlPczRocmZZbTFyX2FwZVpsemVaM1JQcWNzc3RzbldJQXRxSGVCWG51VE05eTFxU3pPb01Zck5V?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics Announces Pricing of $625 Million Upsized Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPdl9ES0JUWDQ5WS1wdkp4dlNFTWdGS05Rd0p3U2x5YTNDOHRaU1hXYXg4aDNsTlE0SE8zYno2S19yTTlzeHFyY213TVkyYXZGVkUwUjF4X05tVTdCNlhHdmhaSnRyNnFGNmVNUHEwVzJ3eVAtQnJ1RTZueGxRRVVpajEzbmFZeWJaOF82ZW04eTJVeUxydlktbkFqa0tLU2xKNFVEcngxWlNjOFdtSUtESkNDSTgwckJ0UGxmeTZZdkZEcVRWY3RYbm93?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics: Go Decision For CIDP Program Warrants Continued Buy Rating (DNTH)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQM25FTmREc0xZN2ZFVFpwZV9TOXZHZDZxcTNjT1ZlNktsMlQ1V1lSY3pvanp1TERKZU1DemFzMTlWMjhXallOX1BWNEhnczR4Qlk5VkwwOFNkdkMyN2VTcVAzMGVCTmVzb1drcFptR2pUTUFKX0lHTmkyV0FER09jRGhfaUl0X2hEUGJkaUJGRDZFQldhbjB3eGwtMmJCN00wSGlzN1BzMHNEUnRyYWFOVFFZTXIwZVJBaW1Lc3FB?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Dianthus prices $625M deal to advance autoimmune drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQMkdKTTZBQy1WOWxBbjJpa1Y1ckpxQTVYTVY1dGluSk5mWU5oN1NVQ2tmdlN5UmEzbkdUakVkUkpZZU16ZUJiTzY0Zm5FQ1U2cDd6bUNERG9IcU1PY2tIVkFnakdiZU96Nk1fcHFDTThnR3VMbUlEMEppSXA2QUlOM2pzeVczSF8xWHE1ak1DakRpUFhqekNsUEduTDdsNzVGRUYxUHJfcGN3WnZxdm1YY1k0NzMzX0NUZnpicU9n?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaluating Dianthus Therapeutics (DNTH) Valuation After A Strong Year Of Share Price Gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNMzZoa2UwU2xHU3JLbG4zTjNRVnYyeVBNd2NBNjE3S0pWQTR1QnBtbDM5ZWFqdlBnVXBsc1czblJUTk4xeER5N3FQbElpV0xHaDB6aWFFUHBCVnRPVzFhMVFERF96SklSR3JTOFMzSHhHSGExZ2FXS3ZVTUVZVUN2Q2hHZzg0Zk1Ea2tLcmdHdW1iZXBrVHNHSA?oc=5", "source_name": "Market source", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus plans $400M share sale to fund autoimmune drug trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPT3lFbXE0cGJIOHJpZ1MwRlItOWFjdkp3em01a0Z4OHhjckJwQ2ZfSVJKYTU1dnJwMG1USlM3dlZaVWItX0kyVFhrTnBWWkI2REtCaC1wWGdJOEkzUVU1cDRwWGZaMVJ2TkhPSVc3UlhzWjR2Z0dfbkFPQ0plbmF5eWxlYXBveFdWQ3FodDBWc3VZYTdzX1MzRVJsQnhFVUIteFFLR2Z5QnFGRDh1YU8wMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics, Inc. (DNTH) Stock Jumps 12.0%: Will It Continue to Soar?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOaUZQbURjZmFQVVphYUhBLWpsU1I5TVRSUW8wOVgzV3kwYThyT2g0WVdZVS1pamtKWkdhRVpGMHYyWnZDRVZLYUhjUjRiamJNTkFLWUNSclUyVmJzRGpSWHMwLW05WG9BSEtZWHQ3WktPeGMtbTd0eFdsWEg1WkdEQ1BEX2YzcnRXemc?oc=5", "source_name": "Market source", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Form 4 Dianthus Therapeutics Inc For: 13 July By Investing.com", "summary": "This article from Investing.com reports that Dianthus Therapeutics Inc. submitted a Form 4 on July 13. The company's stock symbol is DNTH, and it experienced a slight increase of 0.96% at the time of publication. The brief report serves as an announcement for the financial filing", "url": "https://ng.investing.com/news/stock-market-news/form-4-dianthus-therapeutics-inc-for-13-july-93CH-2597649", "source_name": "Investing.com Nigeria", "published_at": "2026-07-13T22:14:00", "published_display": "13 Jul 2026 22:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus therapeutics CFO Ryan Savitz sells $3.16 million in shares", "summary": "Dianthus Therapeutics CFO Ryan Savitz sold 31,249 shares of common stock for approximately $3.16 million on July 9, 2026, through a Rule 10b5-1 trading plan. This sale occurred after he exercised stock options to acquire the same number of shares, which were vested monthly over f", "url": "https://www.investing.com/news/insider-trading-news/dianthus-therapeutics-cfo-ryan-savitz-sells-316-million-in-shares-93CH-4789441", "source_name": "Investing.com", "published_at": "2026-07-13T21:41:03", "published_display": "13 Jul 2026 21:41", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Dianthus Therapeutics, Inc. /DE/ Insider Trading Activity", "summary": "Dianthus Therapeutics' EVP, CFO & CBO, Ryan Savitz, exercised stock options for 31,249 shares and subsequently sold them in open-market transactions for approximately $3.16 million, as detailed in a recent Form 4 filing. These sales were conducted under a Rule 10b5-1 trading plan", "url": "https://www.stocktitan.net/sec-filings/DNTH/form-4-dianthus-therapeutics-inc-de-insider-trading-activity-8c7fd1efe021.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:41:03", "published_display": "13 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics (DNTH) Starts Phase 3 EMERGE Trial, Is The Upside Already Priced In?", "summary": "Dianthus Therapeutics (DNTH) has initiated its Phase 3 EMERGE trial for claseprubart in generalized Myasthenia Gravis, and the stock has experienced significant appreciation recently. Despite a high valuation compared to the broader biotech industry, it appears undervalued agains", "url": "https://www.sahmcapital.com/news/content/dianthus-therapeutics-dnth-starts-phase-3-emerge-trial-is-the-upside-already-priced-in-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-11T02:40:38", "published_display": "11 Jul 2026 02:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing", "summary": "This article details a Form 144 SEC filing by Dianthus Therapeutics, Inc. (DNTH) concerning a proposed sale of 31,249 common shares with an aggregate market value of $3,064,589.43. The shares were acquired on July 9, 2026, through the exercise of stock options and are intended to", "url": "https://www.stocktitan.net/sec-filings/DNTH/144-dianthus-therapeutics-inc-de-sec-filing-220316c7136d.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:03:53", "published_display": "09 Jul 2026 20:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Dianthus Therapeutics, Inc. \u2013 MUN:87E", "summary": "The article provides a simple statement about the \"Price to earnings forward\" for Dianthus Therapeutics, Inc. (MUN:87E) on the Munich Stock Exchange. It indicates no trading activity and shows a placeholder for a period, value, and change, suggesting that specific financial data ", "url": "https://www.tradingview.com/symbols/MUN-87E/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T11:10:38", "published_display": "08 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Dianthus Therapeutics, Inc. \u2013 NASDAQ:DNTH", "summary": "This article provides an analysis of the enterprise value to revenue forward for Dianthus Therapeutics, Inc. (NASDAQ: DNTH). It appears to be a financial snapshot from TradingView, highlighting key financial metrics for the company. The content focuses on the valuation of the com", "url": "https://www.tradingview.com/symbols/NASDAQ-DNTH/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T04:11:21", "published_display": "06 Jul 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DNTH - Dianthus Therapeutics Inc Revenue Breakdown", "summary": "This article provides a comprehensive financial overview of Dianthus Therapeutics Inc (DNTH), detailing its revenue breakdown, key financial metrics, stock performance, and insider/institutional ownership. It includes various ratios like P/S, P/B, and profitability margins, along", "url": "https://finviz.com/stock?t=DNTH&ta=1&p=d&ty=rv&b=2", "source_name": "Finviz", "published_at": "2026-07-05T13:44:31", "published_display": "05 Jul 2026 13:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)", "summary": "Dianthus Therapeutics, Inc. announced that it granted equity awards to five newly-hired, non-executive employees on July 1, 2026. These inducement grants, approved by the independent Compensation Committee, consist of non-qualified stock options to purchase an aggregate of 58,000", "url": "https://finance.yahoo.com/healthcare/articles/dianthus-therapeutics-announces-inducement-grants-200100668.html", "source_name": "Market source", "published_at": "2026-07-03T12:10:57", "published_display": "03 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus gives 5 new hires stock options worth 58,000 shares", "summary": "Dianthus Therapeutics granted 58,000 non-qualified stock options to five new non-executive employees on July 1, 2026, as an inducement under Nasdaq Listing Rule 5635(c)(4). These options have a 10-year term, an exercise price of $90.21 per share, and a four-year vesting schedule.", "url": "https://www.stocktitan.net/news/DNTH/dianthus-therapeutics-announces-inducement-grants-under-nasdaq-2dq42355f5jn.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:40:34", "published_display": "02 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics (DNTH) Starts Phase 3 Trial, Is The Stock Still A Bargain?", "summary": "Dianthus Therapeutics (DNTH) is gaining attention after initiating its EMERGE global Phase 3 trial for claseprubart in generalized Myasthenia Gravis, following positive Phase 2 data and Orphan Drug Designation. Despite recent volatility and removal from Russell indices, the stock", "url": "https://www.sahmcapital.com/news/content/dianthus-therapeutics-dnth-starts-phase-3-trial-is-the-stock-still-a-bargain-2026-07-02", "source_name": "Sahm", "published_at": "2026-07-02T13:44:31", "published_display": "02 Jul 2026 13:44", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Dianthus Therapeutics, Inc. \u2013 NASDAQ:DNTH", "summary": "This article provides a financial metric, \"Price to book forward,\" for Dianthus Therapeutics, Inc. (NASDAQ: DNTH). It is presented on the TradingView platform, which offers various financial tools and data for investors. The content is primarily a listing of navigation and footer", "url": "https://www.tradingview.com/symbols/NASDAQ-DNTH/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T22:39:20", "published_display": "01 Jul 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Dianthus Therapeutics (DNTH) Is Up 11.4% After Launching Its Phase 3 EMERGE gMG Trial", "summary": "Dianthus Therapeutics saw its stock rise by 11.4% after initiating the global Phase 3 EMERGE trial for its investigational antibody claseprubart in generalized Myasthenia Gravis (gMG). This follows promising Phase 2 data and FDA Orphan Drug Designation. The trial aims to offer an", "url": "https://www.sahmcapital.com/news/content/why-dianthus-therapeutics-dnth-is-up-114-after-launching-its-phase-3-emerge-gmg-trial-2026-07-01", "source_name": "Sahm", "published_at": "2026-06-30T12:40:27", "published_display": "30 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics stock hits 52-week high at 96.85 USD", "summary": "Dianthus Therapeutics (DNTH) stock has hit a new 52-week high of $96.85, achieving a market capitalization of $5.21 billion and demonstrating significant growth with a 1-year total return of over 440%. Despite an InvestingPro analysis suggesting it may be overvalued, the company'", "url": "https://www.investing.com/news/company-news/dianthus-therapeutics-stock-hits-52week-high-at-9685-usd-93CH-4765607", "source_name": "Investing.com", "published_at": "2026-06-29T14:40:21", "published_display": "29 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics stock hits 52-week high at 96.85 USD By Investing.com", "summary": "Dianthus Therapeutics stock has reached a 52-week high of $96.85, pushing its market capitalization to $5.21 billion, despite an InvestingPro analysis suggesting it might be overvalued. The company has seen significant growth with a 440.84% 1-year return and 131% year-to-date gai", "url": "https://ca.investing.com/news/stock-market-news/dianthus-therapeutics-stock-hits-52week-high-at-9685-usd-93CH-4711951", "source_name": "Investing.com Canada", "published_at": "2026-06-29T13:39:43", "published_display": "29 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 84, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics Begins Phase 3 Trial of Treatment for Rare Autoimmune Disorder", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/dianthus-therapeutics-begins-phase-3-120515696.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:05:15+00:00", "published_display": "29 Jun 2026 12:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis", "summary": "Dianthus Therapeutics has initiated the Phase 3 EMERGE trial for claseprubart, a treatment for generalized Myasthenia Gravis (gMG). This global, randomized, placebo-controlled study will evaluate subcutaneous doses of claseprubart in approximately 195 participants, with top-line ", "url": "https://www.manilatimes.net/2026/06/29/tmt-newswire/globenewswire/dianthus-therapeutics-announces-initiation-of-phase-3-emerge-trial-of-claseprubart-in-generalized-myasthenia-gravis/2374736", "source_name": "The Manila Times", "published_at": "2026-06-29T10:39:43", "published_display": "29 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus launches Phase 3 study of claseprubart in rare muscle disease", "summary": "Dianthus Therapeutics has initiated the global Phase 3 EMERGE trial for claseprubart in patients with generalized myasthenia gravis (gMG) who are AChR+. This placebo-controlled study will involve approximately 195 participants to evaluate subcutaneous dosing regimens (Q2W and Q4W", "url": "https://www.stocktitan.net/news/DNTH/dianthus-therapeutics-announces-initiation-of-phase-3-emerge-trial-3bfqpf2ebwxk.html", "source_name": "Stock Titan", "published_at": "2026-06-29T10:39:43", "published_display": "29 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics, Inc.(NasdaqCM: DNTH) dropped from Russell 3000E Index", "summary": "Dianthus Therapeutics, Inc. (NasdaqCM:DNTH) has been removed from the Russell 3000E Index. The company, a clinical-stage biotechnology firm, focuses on developing therapies for severe autoimmune diseases with lead candidates like claseprubart and DNTH212. Recent news includes pre", "url": "https://www.marketscreener.com/news/dianthus-therapeutics-inc-nasdaqcm-dnth-dropped-from-russell-3000e-index-ce7f5fdede89f622", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T09:48:47", "published_display": "29 Jun 2026 09:48", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell Microcap Growth Benchmark Index", "summary": "Dianthus Therapeutics, Inc. (NasdaqCM:DNTH) has been removed from the Russell Microcap Growth Benchmark Index. The company is a clinical-stage biotechnology firm developing therapies for severe autoimmune diseases, with its lead candidate, claseprubart, undergoing multiple clinic", "url": "https://www.marketscreener.com/news/dianthus-therapeutics-inc-nasdaqcm-dnth-dropped-from-russell-microcap-growth-benchmark-index-ce7f5fded08df721", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T08:40:00", "published_display": "29 Jun 2026 08:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Dianthus Therapeutics, Inc. \u2013 NASDAQ:DNTH", "summary": "This article provides financial information for Dianthus Therapeutics, Inc. (NASDAQ: DNTH), specifically its price-to-sales forward metric. The content was sourced from TradingView and includes data from ICE Data Services and FactSet.", "url": "https://www.tradingview.com/symbols/NASDAQ-DNTH/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T22:39:43", "published_display": "28 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Dianthus Therapeutics, Inc. \u2013 NASDAQ:DNTH", "summary": "This article provides the \"Price to earnings forward\" value for Dianthus Therapeutics, Inc. (NASDAQ: DNTH). It appears to be an unpopulated data point from a financial platform like TradingView, indicating that the specific financial metric is not available for the company at the", "url": "https://www.tradingview.com/symbols/NASDAQ-DNTH/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T16:09:43", "published_display": "28 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DNTH - Dianthus Therapeutics Inc Options", "summary": "This article provides a comprehensive financial snapshot of Dianthus Therapeutics Inc (DNTH), a biotechnology company. It details key financial metrics including market capitalization, revenue, earnings, insider and institutional ownership, profitability ratios, and stock perform", "url": "https://finviz.com/stock?t=DNTH&ta=1&p=d&ty=oc&b=2&ov=chain_strike&s=75", "source_name": "Finviz", "published_at": "2026-06-28T12:10:57", "published_display": "28 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Dianthus Therapeutics, Inc. \u2013 DUS:87E", "summary": "This article provides the \"Price to book forward\" for Dianthus Therapeutics, Inc. (DUS:87E) on the Dusseldorf Stock Exchange. It indicates that the market is currently closed with no trades recorded. The content seems to be a financial data point from a trading platform.", "url": "https://www.tradingview.com/symbols/DUS-87E/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:42:03", "published_display": "28 Jun 2026 06:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DNTH Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast for Dianthus Therapeutics, Inc. (DNTH) stock, including a 1-year price target of 127.85 USD based on 13 analysts. It details recent stock performance, analyst estimates for future prices ranging from 98.00 USD to 200.00 USD, and financial metrics s", "url": "https://www.tradingview.com/symbols/NASDAQ-DNTH/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T09:42:04", "published_display": "27 Jun 2026 09:42", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics, Inc. Actuals & Estimates (FWB:87E)", "summary": "This article provides an overview of Dianthus Therapeutics, Inc. (FWB:87E) financial actuals and estimates, stock performance, and analyst forecasts. It covers the current stock price, historical highs and lows, market capitalization, earnings reports, and volatility. The company", "url": "https://www.tradingview.com/symbols/FWB-87E/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:41:51", "published_display": "26 Jun 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A3ERZ4 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Dianthus Therapeutics, Inc. (A3ERZ4) stock, including analyst price targets, historical performance, and key financial metrics. It details the company's valuation, earnings, revenue, and market capitalization, offering insights into its stock ", "url": "https://www.tradingview.com/symbols/LSX-A3ERZ4/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T13:39:53", "published_display": "25 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus (DNTH) SVP uses 10b5-1 plan to sell 30,000 shares", "summary": "Dianthus Therapeutics' SVP and General Counsel, Adam M. Veness, reported an exercise-and-sale transaction involving 30,000 shares of company stock. He exercised stock options at $17.88 per share and subsequently sold the same number of shares in open-market transactions under a R", "url": "https://www.stocktitan.net/sec-filings/DNTH/form-4-dianthus-therapeutics-inc-de-insider-trading-activity-bf0f74c97bb0.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:40:19", "published_display": "18 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus CIDP Data Lift Prospects While Funding And Dilution Risks Linger", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/dianthus-cidp-data-lift-prospects-110917568.html", "source_name": "Simply Wall St.", "published_at": "2026-06-15T11:09:17+00:00", "published_display": "15 Jun 2026 11:09", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Dianthus Therapeutics stock plunging today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPMlYxTVR2dHhDSVhxd0xjQV84NUFob1NDWXpHYlZPX1hlZ2xRYW50eW01QkJTYXNYekdVTUxZX2phZ3EyQUEyWE5sWl9pcjlYUDFUTmE3Nkp1STJmRE5xMHBWWnZZalZBeVBRS0hDQTdPTEVfRll3RmhJTnJScE9WanJVZUhFcHRyT0dRWlVsZ3ByS0psempReVdQd0dXRFdrT0JnQkYxUktzVkhCaDVFdw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus drops as Sanofi halts trial for peer drug (DNTH)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPUmJuYTNodk13NTgxdGFJNHZvdExsVUZ2cl9pVHJvbjA1eF85cDVxOF85SEdhYWxiLXQ3NmdGdWRRMEY1S0RiNkw1NWZrTFhmV2E1NWVsUTVZUTNsdTBxYWRwSVB5RTU2MThMTUpqVUpJdy02QzNfa1MxN1UtVFVudUhIOEtRamdG?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQREtnY2xmZ0NTV3V5TmRPRG9CN1dLZ0hPbHNYb3RsdWtoSGdCX3U2QkhMUk1aM2tKcWtUbjJ5VjFJRXpCREZhLWlodldUekd1M0xNVjFZSVF2a2xuYVZNWTZXYlZCb0RZODJMUlVEQzM2Y2lva2NoVEdoTlA0NF9XUml1bWZqWkFVWHNkdG1pYkRLUzluZlI0eUlWRzVXYkU5bzNDRE05RnFJODFuakluQkhrNms?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNRUVBTUtfWWZpUU14T3RxRURWWEZERlJBb0hSNEdOQlBZQXhQU0tBbnl1R1ZWYnk5M3NJNmZmcFVmNDI3TWJGV2h3VW85dTQ0VXRoeENQLW9VWEhtTVRrc282YnN1ZDFZLWMxWmpDWDBnZExRa0d6NC1uNS04S1FBMXdWSUxZXzdudGt3OGtaalVCY05rMl9ZajFNS0JqbVh6eXhiUDJB?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DNTH (NASDAQ) director files Form 144 to sell 26,530 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNMi0wMkZaR1dCLVpodUo1QWZFLVpDRW9MeWFrSXMyWUNfQWNxa0RINUttZS1sc3ZrOGVyc1NIcERKb1lMc2hfcW5aY0J0a0liMkNSTzEzc0JacU1GLVVYUkxtTUtySlQtN21NNHYxTDlxUGxuMWlqQzhsT1lrSHI1OXZjclByQzFuZmlMM0doNlFCcWkyNTVWRGMyejBKUjJ0ZXJyS2lCQUk?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Dianthus to meet investors at Jefferies and Goldman events", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOYWJDNnVNejZCbkpIUklOaTRIWkk4ckhDMU5rVFNrVWRoRFd5S3gyZTNsSDhKWFEyZzEyaGxFVXRybk1FalBmX1JqZU5JZkdMYi1neG1IRkw5NDd0NENtd2lfUUlIM21uanJfXy16c19WSV9LNk9yOGk1QzdHeXU0RmtjWUZLTXBsMkFNOVBaVTJqZldJZEFfTUVnc2RIcmdLQVhlOElzOWR3SEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOR1BicF9Ma2kzSmpXeV95c1dxNG9vUkdVSmRFdklyYU80MDFhWE9lV2VqQU1TM0lSYS1abkxWSE9hUm82bXZKb1JUTEdrVk9weGNWNldjRU95OWx5QkVlZ1NVOW81M1dlU1NBR3NDa2xSUU9YeUJBaHRvTnVwOWc2cTdwMTJDUjNkS0RFZGxUZ0VGSk5MWnVmUlp2LU1sOUJoVk9ZMHdTUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus got 20 responders before 40 patients in CIDP trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOejJVVWZfS254RF9oZUdiS0Zwb1hNaF9Ha0pNR0hLSHJYYkxSN1FacmYtOXRBQjZFMEpkS2NRQ3RodThrc2hxTjA0NXZuVHJtS0NSUzdwbk1WaXNtUlZ5ZlE4WmJHczh0cWZvUVpZSEU5V3ZzNElQSHFMeEtmcVhPNld1LXZTQW5uQ1FFTDNXWmFPWkpTWklUVWlkU280ZWdHSXhrWklOcXJNTWh1S0VqRUx3ZHJXVkFFN185SQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQTHJ2eHdfZ2N3cXd3NVB3c01iV1plZGRMZ3dTSER4RmtFYU1FazdiOHkwbE4xR2dsR3FpVlRnR012dXVvVkx1X3UzS2tNR0RranZvU1lOdkd1ZmdfajFmYXV2X1BWZG0wWjlobDZNMXB0eV93QUdtVDBkaTBWSmxVd3VEWUtfMGxtWTNUTmtyT2ttM0lacTRXUmg5WUdYaTdBSmtWc0JPMDlwb2s?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPblBaR0hLZ3lSSTdjZThTSWFuV3VkTkVRZ3ZJeWp2SXEyQWhnNmlrUmFiNlhNZWttaVZmc01tSDBWbmZnTlhXVVpsTmNfNWtTV25VR1lQekx6bzczeEZSQ0hwN3dsZ1BUNnRaTDl5MG01eFM3M2JPcVRmUWxBUzlVZDNrWHRoSThJdEJEQzlDRmVTQUlMSnJBenZIVVRka2NFcUFySl96bw?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Dianthus raises $719M to push autoimmune disease drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNeDZseEVCOG1Bajg2UVJyVTlDYmtTRGk0NUtndXh3anE1Z2w3VEtsVXZGRzBrWmFEVWthY0VWSVpGS3NVeEdHbnp4VE91VktMcVZ6dmQ4YXpNNW9HZkhFcm90a0s0VTczNEZ5RlFPQW5rMUxIT2tDTHhIUnplQzlqeWlPczRocmZZbTFyX2FwZVpsemVaM1JQcWNzc3RzbldJQXRxSGVCWG51VE05eTFxU3pPb01Zck5V?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics Announces Pricing of $625 Million Upsized Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPdl9ES0JUWDQ5WS1wdkp4dlNFTWdGS05Rd0p3U2x5YTNDOHRaU1hXYXg4aDNsTlE0SE8zYno2S19yTTlzeHFyY213TVkyYXZGVkUwUjF4X05tVTdCNlhHdmhaSnRyNnFGNmVNUHEwVzJ3eVAtQnJ1RTZueGxRRVVpajEzbmFZeWJaOF82ZW04eTJVeUxydlktbkFqa0tLU2xKNFVEcngxWlNjOFdtSUtESkNDSTgwckJ0UGxmeTZZdkZEcVRWY3RYbm93?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics: Go Decision For CIDP Program Warrants Continued Buy Rating (DNTH)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQM25FTmREc0xZN2ZFVFpwZV9TOXZHZDZxcTNjT1ZlNktsMlQ1V1lSY3pvanp1TERKZU1DemFzMTlWMjhXallOX1BWNEhnczR4Qlk5VkwwOFNkdkMyN2VTcVAzMGVCTmVzb1drcFptR2pUTUFKX0lHTmkyV0FER09jRGhfaUl0X2hEUGJkaUJGRDZFQldhbjB3eGwtMmJCN00wSGlzN1BzMHNEUnRyYWFOVFFZTXIwZVJBaW1Lc3FB?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Dianthus prices $625M deal to advance autoimmune drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQMkdKTTZBQy1WOWxBbjJpa1Y1ckpxQTVYTVY1dGluSk5mWU5oN1NVQ2tmdlN5UmEzbkdUakVkUkpZZU16ZUJiTzY0Zm5FQ1U2cDd6bUNERG9IcU1PY2tIVkFnakdiZU96Nk1fcHFDTThnR3VMbUlEMEppSXA2QUlOM2pzeVczSF8xWHE1ak1DakRpUFhqekNsUEduTDdsNzVGRUYxUHJfcGN3WnZxdm1YY1k0NzMzX0NUZnpicU9n?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaluating Dianthus Therapeutics (DNTH) Valuation After A Strong Year Of Share Price Gains", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNMzZoa2UwU2xHU3JLbG4zTjNRVnYyeVBNd2NBNjE3S0pWQTR1QnBtbDM5ZWFqdlBnVXBsc1czblJUTk4xeER5N3FQbElpV0xHaDB6aWFFUHBCVnRPVzFhMVFERF96SklSR3JTOFMzSHhHSGExZ2FXS3ZVTUVZVUN2Q2hHZzg0Zk1Ea2tLcmdHdW1iZXBrVHNHSA?oc=5", "source_name": "Market source", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus plans $400M share sale to fund autoimmune drug trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPT3lFbXE0cGJIOHJpZ1MwRlItOWFjdkp3em01a0Z4OHhjckJwQ2ZfSVJKYTU1dnJwMG1USlM3dlZaVWItX0kyVFhrTnBWWkI2REtCaC1wWGdJOEkzUVU1cDRwWGZaMVJ2TkhPSVc3UlhzWjR2Z0dfbkFPQ0plbmF5eWxlYXBveFdWQ3FodDBWc3VZYTdzX1MzRVJsQnhFVUIteFFLR2Z5QnFGRDh1YU8wMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dianthus Therapeutics, Inc. (DNTH) Stock Jumps 12.0%: Will It Continue to Soar?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOaUZQbURjZmFQVVphYUhBLWpsU1I5TVRSUW8wOVgzV3kwYThyT2g0WVdZVS1pamtKWkdhRVpGMHYyWnZDRVZLYUhjUjRiamJNTkFLWUNSclUyVmJzRGpSWHMwLW05WG9BSEtZWHQ3WktPeGMtbTd0eFdsWEg1WkdEQ1BEX2YzcnRXemc?oc=5", "source_name": "Market source", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 54, "sentiment_summary": {"positive": 14, "negative": 7, "neutral": 33, "score": 54, "total": 54, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 18.5, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 7.7, "count": 16}, {"event": "analyst", "label": "Analyst action", "weight": 1.45, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 97.6, "latest_week": "2026-07-10", "one_week_move": 3.5, "four_week_move": 18.9, "twelve_week_move": 4.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.177017, "market_dynamics_buy_signal": false, "relative_strength": 56.198918, "fair_value_gap": 194.3, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 52.6786, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+3.5% over one week, +18.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "Stock Titan", "count": 11}, {"label": "TradingView", "count": 10}, {"label": "Investing.com", "count": 3}, {"label": "Sahm", "count": 3}, {"label": "Finviz", "count": 2}, {"label": "www.marketscreener.com", "count": 2}, {"label": "Seeking Alpha", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 16}, {"label": "Analyst action", "count": 2}, {"label": "Deals and strategy", "count": 2}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+3.5% over one week, +18.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Form 4 Dianthus Therapeutics Inc For: 13 July By Investing.com"}], "updated_at": "2026-07-16T00:45:14.204691+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}